KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual Obligations AnnualCost Of SalesDistribution Revenue By SegmentDistribution Revenue By Segment AnnualEmployee StatisticsEurope Revenue By CategoryEurope Revenue By Category AnnualFacility Count By RegionGross Margin %Gross Margin By Segment %Gross ProfitGross Profit By SegmentIncome Before Income Taxes By RegionInternational Markets Revenue By CategoryInternational Markets Revenue By Category AnnualInventories BreakdownLicensing Arrangements Revenue By SegmentLicensing Arrangements Revenue By Segment AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %North America Revenue By CategoryNorth America Revenue By Category AnnualOpex As A % Of RevenueOPEX SegregationOther Revenue By SegmentOther Revenue By Segment AnnualPharmaceutical Manufacturing SitesProperty, Plant And Equipment By Geographical LocationProperty, Plant & Equipment BreakdownRevenue By Businesss Vertical AnnualRevenue By Businesss Vertical Annual %Revenue By Business VerticalRevenue By Business Vertical %Revenue By Business Vertical AnnualRevenue By Business Vertical Annual %Revenue By CustomerRevenue By Customer %Revenue By Major ProductsRevenue By Major Products %Revenue By Major Products AnnualRevenue By Major Products Annual %Revenue By Region AnnualRevenue By Region Annual %Revenue By SegmentRevenue By Segment %Sale Of Goods Revenue By SegmentSale Of Goods Revenue By Segment AnnualSegment ProfitSegment Profit AnnualSegment Profit Margin %Segment Profit Margin Annual %Square Footage By RegionWorkforce Headcount By Region
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Gross Profit: 2009-2024

Historic Gross Profit for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $8.1 billion.

  • Teva Pharmaceutical Industries' Gross Profit rose 7.26% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 billion, marking a year-over-year increase of 0.55%. This contributed to the annual value of $8.1 billion for FY2024, which is 5.48% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Gross Profit stood at $8.1 billion for FY2024, which was up 5.48% from $7.6 billion recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Gross Profit ranged from a high of $8.1 billion in FY2024 and a low of $7.0 billion during FY2022.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Gross Profit value was $7.6 billion (recorded in 2023), while the average stood at $7.6 billion.
  • Its Gross Profit has fluctuated over the past 5 years, first fell by 8.18% in 2022, then climbed by 9.64% in 2023.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Gross Profit stood at $7.7 billion in 2020, then fell by 1.71% to $7.6 billion in 2021, then declined by 8.18% to $7.0 billion in 2022, then rose by 9.64% to $7.6 billion in 2023, then grew by 5.48% to $8.1 billion in 2024.